Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
32 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Hyundai Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Hyundai Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Hyundai Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Hyundai Pharmaceutical Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Hyundai Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Hyundai Pharmaceutical Co., Ltd.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Hyundai Pharmaceutical Co., Ltd.'s pipeline products Reasons to buy - Evaluate Hyundai Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Hyundai Pharmaceutical Co., Ltd. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Hyundai Pharmaceutical Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Hyundai Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Hyundai Pharmaceutical Co., Ltd. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Hyundai Pharmaceutical Co., Ltd. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Hyundai Pharmaceutical Co., Ltd. Snapshot 5 Hyundai Pharmaceutical Co., Ltd. Overview 5 Key Information 5 Key Facts 5 Hyundai Pharmaceutical Co., Ltd. - Research and Development Overview 6 Key Therapeutic Areas 6 Hyundai Pharmaceutical Co., Ltd. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Hyundai Pharmaceutical Co., Ltd. - Pipeline Products Glance 12 Hyundai Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 Hyundai Pharmaceutical Co., Ltd. - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Discovery Products/Combination Treatment Modalities 15 Hyundai Pharmaceutical Co., Ltd. - Drug Profiles 16 NZ-419 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 choline alfoscerate SR 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 HOB-048 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 HOB-051 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 HD-0471042 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 HD-0471953 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 UHC-1 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 HOB-046 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 HOB-047 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Hyundai Pharmaceutical Co., Ltd. - Pipeline Analysis 25 Hyundai Pharmaceutical Co., Ltd. - Pipeline Products by Target 25 Hyundai Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration 26 Hyundai Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type 27 Hyundai Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action 28 Hyundai Pharmaceutical Co., Ltd. - Dormant Projects 29 Hyundai Pharmaceutical Co., Ltd. - Locations And Subsidiaries 30 Head Office 30 Appendix 31 Methodology 31 Coverage 31 Secondary Research 31 Primary Research 31 Expert Panel Validation 31 Contact Us 32 Disclaimer 32
List of Tables Hyundai Pharmaceutical Co., Ltd., Key Information 5 Hyundai Pharmaceutical Co., Ltd., Key Facts 5 Hyundai Pharmaceutical Co., Ltd. - Pipeline by Indication, 2014 7 Hyundai Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2014 8 Hyundai Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2014 9 Hyundai Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2014 10 Hyundai Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 11 Hyundai Pharmaceutical Co., Ltd. - Phase II, 2014 12 Hyundai Pharmaceutical Co., Ltd. - Phase I, 2014 13 Hyundai Pharmaceutical Co., Ltd. - Preclinical, 2014 14 Hyundai Pharmaceutical Co., Ltd. - Discovery, 2014 15 Hyundai Pharmaceutical Co., Ltd. - Pipeline by Target, 2014 25 Hyundai Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2014 26 Hyundai Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2014 27 Hyundai Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2014 28 Hyundai Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2014 29
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.